Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome.

Abstract

We describe 2 children with postinfectious opsoclonus-myoclonus syndrome. Although the patients initially responded to monotherapy with methylprednisolone, intravenous immunoglobulins, or rituximab, they manifested persistent neurologic deficits and relapsing signs. Treatment with rituximab in combination with intravenous immunoglobulin, however, resulted in significant longterm clinical improvement.

• Authors: Wilhelmina G Leen, Corry M Weemaes, Marcel M Verbeek, Michèl A Willemsen, Jan J Rotteveel
• Journal: Pediatric neurology (Pediatr Neurol) Vol. 39 Issue 3 Pg. 213-7 (Sep 2008) ISSN: 0887-8994 [Print] United States
• PMID: 18725071 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Immunoglobulins, Intravenous
• Immunologic Factors
• Rituximab

Topics

• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Drug Therapy, Combination
• Female
• Humans
• Immunoglobulins, Intravenous (administration & dosage, therapeutic use)
• Immunologic Factors (administration & dosage, therapeutic use)
• Infant
• Opsoclonus-Myoclonus Syndrome (drug therapy, pathology)
• Recurrence
• Rituximab
• Treatment Outcome